Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Sponsor
Alexion Pharmaceuticals, Inc.
Study ID
NCT06967480
Status
Recruiting
Apply to this trial

Conditions

  • Anti-AChR Antibody Positive
  • Generalized Myasthenia Gravis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ravulizumab — DRUG
    Participants will receive Ravulizumab.

Study Details

The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.

Key Dates

First listed
May 13, 2025
Start date
Jul 31, 2025
Status verified
Feb 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Ravulizumab
    Participants will receive Ravulizumab until Week 50 ± 14 days after baseline or until discontinuation.

Primary Outcome Measure

Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 50 [ Time Frame: Week 50 ]

Central Contacts

Related Studies